Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.